TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03881111
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle. Duration of cisplatin treatment will be capped at 6 doses.
Study: NCT03881111
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 mg/m\^2/day (4000 mg/m\^2 total per cycle) administered as continuous IV infusion on Days 1 to 5 (120 hours) of each 3-week cycle, or per local standard for 5-FU administration.
Study: NCT00210301
Drug: Provigil (modafinil)
Normalized name: modafinil Oral Tablet [Provigil]
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00623324
Drug: Aplindore
Normalized name: Aplindore
DrugBank: Aplindore (DB06620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets .05 - 5 mg BID dosing for 14 days
Study: NCT00364286
Drug: Dasatinib (BMS-354825)
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 50mg Orally twice daily
Study: NCT00998036
Drug: Temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Temsirolimus will be administered intravenously weekly on days one and eight of a three week cycle. Temsirolimus will not be given on week three (usually dosed weekly) for increased tolerability given its possible plasma accumulation during week three. Temsirolimus will be given second over a 30 minute infusion during posthydration.~Dose escalation will follow the standard 3 by 3 design with three set dosing levels.~Dose Level 1: Temsirolimus 15mg~Dose Level 2: Temsirolimus 15mg~Dose Level 3: Temsirolimus 25mg
Study: NCT00998036
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin at 30mg/m2 will be administered intravenously weekly on days one and eight of a three week cycle. Cisplatin will be given first over a 30 minute infusion with prehydration.
Study: NCT00998036
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib will be taken by mouth daily starting at 100mg. On days of cisplatin and temsirolimus infusions, erlotinib should be taken at least two hours after the beginning of the temsirolimus infusion.~Dose escalation will follow the standard 3 by 3 design with three set dosing levels.~Dose Level 1: Erlotinib 100mg~Dose Level 2: Erlotinib 150mg~Dose Level 3: Erlotinib 150mg
Study: NCT03591718
Drug: BI 456906
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection
Study: NCT03159559
Drug: Lipo-PGE1
Normalized name: PGE1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients received conventional therapy plus Lipo-PGE1 10μg once daily intravenous injection for 7 days
Study: NCT01337336
Drug: fluticasone propionate/salmeterol xinafoate
Normalized name: Fluticasone Propionate/Salmeterol Xinafoate 0.1 MG/1 ACTUATION-0.05 MG/1 ACTUATION Inhalation Disk
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: combination fluticasone priopionate and salmeterol xinafoate 250/50mcg
Study: NCT03393494
Drug: Adapalene and Benzoyl Peroxide Topical Gel
Normalized name: adapalene / benzoyl peroxide
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Test product
Study: NCT06375070
Drug: anticoagulant
Normalized name: Anticoagulant
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rivaroxaban
Study: NCT02814643
Drug: Benralizumab
Normalized name: Benralizumab
DrugBank: Benralizumab (DB12023)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Benralizumab SC administered every 4 weeks for 3 doses (Weeks 0, 4, and 8).
Study: NCT02814643
Drug: Benralizumab Placebo
DrugBank: Benralizumab (DB12023)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Placebo administered every 4 weeks for 3 doses (Weeks 0, 4, and 8).
Study: NCT02814643
Drug: Seasonal influenza virus vaccine
Normalized name: influenza A virus
DrugBank: Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (UV, formaldehyde inactivated) (DB10596)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.
Study: NCT00490685
Drug: Sorafenib (BAY-43-9006)
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04992156
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib 125mg/d
Study: NCT00737776
Drug: biphasic insulin aspart 30
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study: NCT00811603
Drug: Cefazolin (Timing of Antibiotic Prophylaxis)
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients scheduled for a cesarean delivery will be randomly assigned to receive Cefazolin (antibiotic prophylaxis) either prior to skin incision or after the clamping of the umbilical cord
Study: NCT02327676
Drug: Emtricitabine
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: emtricitabine were given to each patients for 48 weeks
Study: NCT03003637
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab (240 mg flat dose, week 1 and week 3, twice in total) monotherapy, neoadjuvant to SOC (surgery with or without adjuvant (C)RT).
Study: NCT01833390
Drug: HXe MRI lung ventilation
Normalized name: beef lung preparation
DrugBank: Beef (DB10509)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MagniXene (HXe) is an Investigational New Drug made of xenon noble gas. Through a physical process using alkali vapors and powerful lasers, xenon atoms have their nuclear spin preferentially aligned (hyperpolarized), thus offering a highly enhanced signal inside an MRI scanner. High-resolution images of the lung spaces are acquired within a short breath-hold after inhalation of HXe.
Study: NCT01316380
Drug: tiotropium 2.5 mcg
Normalized name: tiotropium 2.5 mcg/inh inhalation aerosol
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To evaluate efficacy and safety of 2.5 and 5 mcg tiotropium versus placebo delivered via Respimat inhaler
Study: NCT03003637
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab (1 mg/kg) only in week 1, in combination with nivolumab (240 mg flat dose, week 1 and week 3, twice in total), neoadjuvant to SOC (surgery with or without adjuvant (C)RT).
Study: NCT01314352
Drug: Desloratadine
Normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desloratadine Tablets, 5 mg
Study: NCT02174393
Drug: Universal Peel
Normalized name: orange peel extract
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Universal Peel: is a chemical peel consisting of a mild acid solution. (5 min Peel and 5 min Retinol)
Study: NCT01316380
Drug: tiotropium 5 mcg
Normalized name: tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To evaluate efficacy and safety of 2.5 and 5 mcg tiotropium versus placebo delivered via Respimat inhaler
Study: NCT02848963
Drug: Ketamine-propofol mixture
Normalized name: brown mixture
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ratio of Ketamine-propofol mixture will be compare for every groups.
Study: NCT01416402
Drug: Arhalofenate
Normalized name: Arhalofenate
DrugBank: Arhalofenate (DB11811)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg once daily orally for two weeks then up-titrated to 600 mg once daily orally for an additional two weeks
Study: NCT01416402
Drug: Febuxostat
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 80 mg once daily orally for 5 weeks
Study: NCT01416402
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine 0.6 mg daily as prophylaxis to prevent gout flares
Study: NCT03169166
Drug: Triptorelin
Normalized name: triptorelin
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triptorelin pre-filled syringes (Gonapeptyl 0.1mg; Ferring GmbH, Germany) will be administered subcutaneously in three repeated doses 12 hours apart
Study: NCT02174393
Drug: Post-Microneedling Skin Care
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: On Day 1 (after Microneedling procedure):~* Gentle Antioxidant Soothing Cleanser daily~* Soothing Recovery Ointment and Sheer Physical Sunscreen~On Day 2-7:~* AM: Physical sheer sunscreen and recovery ointment~* PM: Retinol/Vitamin C in the evening and soothing recovery ointment~On Day 7:~* AM: BD Hydrating Day/Night Cream~* PM: Retinol and Vitamin C and the BD Hydrating Day/Night Cream (if necessary)
Study: NCT04091425
Drug: TAK-925
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-925 IV infusion
Study: NCT00014794
Drug: 15-O labeled water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03915340
Drug: Propafenone
Normalized name: Propafenone
DrugBank: Propafenone (DB01182)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propafenone is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 300 mg of propafenone hydrochloride.
Study: NCT00006505
Drug: Islet Transplantation
Normalized name: Autologous pancreatic islets
DrugBank: Autologous pancreatic islets (DB18521)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Islet cell transplantation. This study will test whether a new islet transplant procedure will enable patients with type 1 diabetes mellitus to stop insulin therapy
Study: NCT01129232
Drug: GAD-alum
Normalized name: alum
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 µg of GAD-alum injected sc after the biopsy, and repeated after one month
Study: NCT00293917
Drug: Tacrolimus Cream
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01380223
Drug: omecamtiv mecarbil
Normalized name: omecamtiv mecarbil
DrugBank: Omecamtiv Mecarbil (DB11816)
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.005 mg/kg/hr
Study: NCT01380223
Drug: omecamtiv mecarbil
Normalized name: omecamtiv mecarbil
DrugBank: Omecamtiv Mecarbil (DB11816)
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.015 mg/kg/hr
Study: NCT01380223
Drug: omecamtiv mecarbil
Normalized name: omecamtiv mecarbil
DrugBank: Omecamtiv Mecarbil (DB11816)
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.025 mg/kg/hr
Study: NCT01380223
Drug: omecamtiv mecarbil
Normalized name: omecamtiv mecarbil
DrugBank: Omecamtiv Mecarbil (DB11816)
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.0625 mg/kg/hr
Study: NCT01380223
Drug: omecamtiv mecarbil
Normalized name: omecamtiv mecarbil
DrugBank: Omecamtiv Mecarbil (DB11816)
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.125 mg/kg/hr
Study: NCT01380223
Drug: omecamtiv mecarbil
Normalized name: omecamtiv mecarbil
DrugBank: Omecamtiv Mecarbil (DB11816)
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.25 mg/kg/hr
Study: NCT04432688
Drug: Lurasidone HCl
Normalized name: lurasidone HCl
DrugBank: Lurasidone (DB08815)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This is a non-interventional, observational study
Study: NCT01380223
Drug: omecamtiv mecarbil
Normalized name: omecamtiv mecarbil
DrugBank: Omecamtiv Mecarbil (DB11816)
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.5 mg/kg/hr
Study: NCT01380223
Drug: omecamtiv mecarbil
Normalized name: omecamtiv mecarbil
DrugBank: Omecamtiv Mecarbil (DB11816)
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 1.0 mg/kg/hr
Study: NCT01380223
Drug: omecamtiv mecarbil
Normalized name: omecamtiv mecarbil
DrugBank: Omecamtiv Mecarbil (DB11816)
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.75 mg/kg/hr (dose reduced)
Study: NCT01380223
Drug: omecamtiv mecarbil
Normalized name: omecamtiv mecarbil
DrugBank: Omecamtiv Mecarbil (DB11816)
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.625 mg/kg/hr (dose reduced)
Study: NCT01859923
Drug: Delamanid
Normalized name: delamanid
DrugBank: Delamanid (DB11637)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Participants received adult formulation delamanid as per regimen specified in the arm description. Morning dose of the delamanid BID regimen was given within 30 minutes after the start of a standard breakfast meal. The evening dose of the BID dose regimen was given 10 hours post morning dose and within 30 minutes after the start of a standard dinner meal.
Study: NCT01859923
Drug: Delamanid Pediatric Formulation (DPF)
DrugBank: Delamanid (DB11637)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Participants received delamanid as an extemporaneous suspension using the delamanid pediatric dispersible tablet formulation. Morning dose of the delamanid BID/once daily (QD) regimen was given within 30 minutes after the start of a standard breakfast meal. The evening dose of the BID dose regimen was given 10 hours post morning dose and within 30 minutes after the start of a standard meal.
Study: NCT00004124
Drug: bicalutamide
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004124
Drug: goserelin
Normalized name: Goserelin
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004124
Drug: mitoxantrone hydrochloride
Normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004124
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01815008
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel 75 mg daily
Study: NCT01858792
Drug: Belimumab 1 mg/kg
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Belimumab 1 mg/kg IV plus standard therapy; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
Study: NCT01815008
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 81 mg daily
Study: NCT00446550
Drug: afegostat tartrate
Normalized name: tartrate
DrugBank: Afegostat (DB04545)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03435003
Drug: Aprepitant 80 mg Oral Capsule
Normalized name: Aprepitant 80 mg oral capsule
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: aprepitant 80 mg orally one hour prior to scheduled surgery
Study: NCT01858792
Drug: Belimumab 10 mg/kg
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Belimumab 10 mg/kg IV plus standard therapy; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
Study: NCT00300755
Drug: pantoprazole sodium enteric-coated spheroid
Normalized name: pantoprazole
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pediatric spheroids taken daily x 8 weeks
Study: NCT02983617
Drug: Tirabrutinib
Normalized name: Tirabrutinib
DrugBank: Tirabrutinib (DB15227)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally once daily
Study: NCT02983617
Drug: Entospletinib
Normalized name: Entospletinib
DrugBank: Entospletinib (DB12121)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally once daily
Study: NCT02983617
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intravenously
Study: NCT04306354
Drug: Oxytocin nasal spray
Normalized name: oxytocin Nasal Spray
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin nasal spray 24 UI twice daily as adjunctive treatment to conventional treatment during 10 days of detoxification of crack cocaine
Study: NCT00114244
Drug: sorafenib tosylate
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00114244
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00516386
Drug: RhIGF-1
Normalized name: rhIGF-I/rhIGFBP-3
DrugBank: Mecasermin rinfabate (DB14751)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 35-40 mcg/k/dose twice daily SC
Study: NCT02694978
Drug: Ferumoxytol
Normalized name: Ferumoxytol
DrugBank: Ferumoxytol (DB06215)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02694978
Drug: FCM
Normalized name: FCM
DrugBank: Fosfomycin (DB00828)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03435003
Drug: scopolamine transdermal
Normalized name: scopolamine Transdermal System
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: scopolamine transdermal patch one hour prior to scheduled surgery
Study: NCT03435003
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 8 mg intraoperatively
Study: NCT00006326
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00006326
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00006326
Drug: Delavirdine mesylate
Normalized name: Delavirdine Mesylate
DrugBank: Delavirdine (DB00705)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00082498
Drug: SCH-D (vicriviroc)
Normalized name: Vicriviroc
DrugBank: Vicriviroc (DB06652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 will receive 5 mg vicriviroc daily; Group 3 will receive 10 mg vicriviroc daily; and Group 4 will receive 15 mg vicriviroc daily. If at or after Week 16 a participant's viral load has not met certain criteria, a dose increase of vicriviroc may occur and the participant will enter Step 2. As of 10/12/05, patients in Group 2 and any patients who entered Step 2 following virologic failure in Step 1 will be unblinded and offered either 15 mg vicriviroc daily through this study or the option of seeking alternative treatment.
Study: NCT01184664
Drug: Nicotine Patch
Normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Varenicline + nicotine patch
Study: NCT01184664
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants will receive a standard dose of varenicline (12 weeks).
Study: NCT01811706
Drug: Dalfampridine
Normalized name: Dalfampridine
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalfampridine will be provided at an oral dose of 10mg every 12 hours, for 4 weeks period
Study: NCT03754218
Drug: Amnion Membrane Powder
Normalized name: Arsenite anion
DrugBank: Arsenite ion (DB18509)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This sterilized product is composed of lyophilized, gamma-irradiated powder made from amniotic membrane for topical application with the purpose of enhanced wound healing.
Study: NCT00596986
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duloxetine 30mg up to 120mg per day.
Study: NCT02753803
Drug: Evogliptin, Pioglitazone, Evogliptin+Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Evogliptin : Evogliptin 5mg QD Pioglitazone : Pioglitazone 30mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD
Study: NCT02753803
Drug: Pioglitazone, Evogliptin, Evogliptin+Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone : Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD
Study: NCT02753803
Drug: Evogliptin, Evogliptin+Pioglitazone, Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Evogliptin : Evogliptin 5mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Pioglitazone : Pioglitazone 30mg QD
Study: NCT00839371
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: i.v. propofol titration until adequate depth of sedation
Study: NCT00839371
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: i.v. midazolam titration until adequate depth of sedation
Study: NCT00206258
Drug: Pramlintide and glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03435003
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron 4 mg intraoperatively. Ondansetron will be given twice. Once intraoperatively and then post- operatively.
Study: NCT03435003
Drug: Reglan
Normalized name: Reglan
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperatively scheduled Reglan
Study: NCT03435003
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperatively scheduled ondansetron
Study: NCT03435003
Drug: Compazine
Normalized name: Compazine
DrugBank: Prochlorperazine (DB00433)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperatively as needed compazine for breakthrough PONV
Study: NCT03435003
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Reversal with sugammadex
Study: NCT03435003
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous anesthesia will be maintained through IV propofol
Study: NCT03435003
Drug: dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: maintenance of anesthesia in the intervention arm
Study: NCT03435003
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: inhalational anesthesia